Richelle Myriam, Bortlik Karlheinz, Liardet Stéphanie, Hager Corinne, Lambelet Pierre, Baur Markus, Applegate Lee A, Offord Elizabeth A
Department of Nutrition, Nestlé Research Center, Lausanne, Switzerland.
J Nutr. 2002 Mar;132(3):404-8. doi: 10.1093/jn/132.3.404.
Lycopene from fresh and unprocessed tomatoes is poorly absorbed by humans. Absorption of lycopene is higher from processed foods such as tomato paste and tomato juice heated in oil. The aim of the present study was to develop a food-grade lycopene formulation that is bioavailable in humans. A formulation of lycopene named "lactolycopene" has been designed in which lycopene is entrapped with whey proteins. Healthy subjects (n = 33; 13 men and 20 women) participated and were allocated randomly to one of the three treatment groups. After a 3-wk deprivation of dietary lycopene, subjects ingested 25 mg lycopene/d for 8 wk from lactolycopene, tomato paste (positive control) or a placebo of whey proteins while consuming their self-selected diets. Plasma lycopene concentrations reached a maximum after 2 wk of supplementation in both lycopene-treated groups and then a plateau was maintained until the end of the treatment. Increases in plasma lycopene at wk 8 were not different between supplemented groups (mean +/- SEM): 0.58 +/- 0.13 micromol/L with lactolycopene and 0.47 plus minus 0.07 micromol/L with tomato paste, although they were different from the control (P < 0.001). Similar time-concentration curves of lycopene incorporation were observed in buccal mucosa cells. Although lycopene was present mainly as all-trans isomers (>90%) in both lycopene supplements, plasma lycopene enrichment consisted of 40% as all-trans and 60% as cis isomers. The precursor of lycopene, phytofluene, was better absorbed than lycopene itself. The lactolycopene formulation and tomato paste exhibited similar lycopene bioavailability in plasma and buccal mucosa cells in humans.
新鲜未加工番茄中的番茄红素在人体中的吸收率很低。番茄红素在诸如番茄酱和用油加热的番茄汁等加工食品中的吸收率更高。本研究的目的是开发一种在人体中具有生物利用度的食品级番茄红素制剂。已设计出一种名为“乳番茄红素”的番茄红素制剂,其中番茄红素与乳清蛋白结合。33名健康受试者(13名男性和20名女性)参与研究,并被随机分配到三个治疗组之一。在3周的膳食番茄红素剥夺期后,受试者在食用自选饮食的同时,从乳番茄红素、番茄酱(阳性对照)或乳清蛋白安慰剂中每天摄入25毫克番茄红素,持续8周。两个番茄红素治疗组在补充2周后血浆番茄红素浓度达到最高,然后在治疗结束前保持稳定。补充组在第8周时血浆番茄红素的增加没有差异(平均值±标准误):乳番茄红素组为0.58±0.13微摩尔/升,番茄酱组为0.47±0.07微摩尔/升,尽管它们与对照组不同(P<0.001)。在颊黏膜细胞中观察到番茄红素掺入的类似时间-浓度曲线。尽管两种番茄红素补充剂中的番茄红素主要以全反式异构体(>90%)形式存在,但血浆番茄红素富集由40%的全反式异构体和60%的顺式异构体组成。番茄红素的前体八氢番茄红素比番茄红素本身吸收更好。乳番茄红素制剂和番茄酱在人体血浆和颊黏膜细胞中表现出相似的番茄红素生物利用度。